Bristol-Myers Squibb Company, Medarex, Inc. Release: New Ipilimumab Survival Data in Patients with Metastatic Melanoma Presented at American Society of Clinical Oncology Annual Meeting

PRINCETON, N.J.--(BUSINESS WIRE)--Bristol-Myers Squibb Company (NYSE: BMY) and Medarex, Inc. (NASDAQ: MEDX) today announced preliminary survival data for ipilimumab (10 mg/kg monotherapy), an investigational oncology immunotherapy, in previously-treated patients with advanced metastatic melanoma.